TB500 99% White Powder Kanbei High Purity, Premium Nootropic TB500 Raw Powder
TDS 7 Inquiries
114681-65-1
Reagent Grade
99.9%
深圳
yixin
10vials/box 40mg*10vials
2026-08-30
polypeptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceRGD peptide acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation[1]. RGD peptides promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing[2][3].Certificates
-
TDS
Basic Info-
Product Name:
GRGDNP
Other Name:RGD PEPTIDE;H-GLY-ARG-GLY-ASP-ASN-PRO-OH;GRGDNP;GLY-ARG-GLY-ASP-ASN-PRO;RGD PEPTIDE (GRGDNP);Gly-Arg-Gly-Asp-Asn-Ser;REF DUPL: Gly-Arg-Gly-Asp-Asn-Pro;H-Glg-Arg-Gly-Asp-Asn-Pro-OH
CAS No.:114681-65-1
Molecular Formula:C23H38N10O10
InChIKeys:CWAHAVYVGPRZJU-XUXIUFHCSA-N
Molecular Weight:614.61
Exact Mass:614.277222
Categories:
Characteristics-
PSA:
345
XLogP3:-3.41
Density:1.67±0.1 g/cm3(Predicted)
Refractive Index:1.696
Storage Conditions:-15°C
Research-
Class:
Actin-sequestering protein / 43-amino-acid peptide
Status:Research compound — Not FDA approved (investigational: RGN-259 for dry eye / neurotrophic keratitis)
Mechanism:A naturally occurring 43-amino-acid peptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) that binds G-actin (sequesters monomeric actin), preventing F-actin polymerization. Promotes cell migration, angiogenesis, wound healing, and anti-inflammatory responses via integrin-linked kinase (ILK) and HIF-1α/VEGF pathways. TB-500 is the synthetic fragment Ac-LKKTETQ (MW ~895) often sold under this CAS.
Activity note:Thymosin Beta-4 is an actin-binding protein, not a receptor agonist. Functional activity is measured by actin sequestration (Kd ~0.7–1 μM) and cell migration assays, not EC₅₀.
Source:Goldstein AL, et al. Vitam Horm. 2003;66:257–296. RegeneRx RGN-259 clinical program.DOI
Clinical Development:
References-
DrugBank:PubChem:UNII:Disclaimer:
Thymosin Beta-4 (TB-500) is NOT FDA-approved for human therapeutic use. RGN-259 (Tβ4 ophthalmic solution) is an investigational drug not yet approved. TB-500 sold on research-chemical marketplaces is a synthetic fragment and is not an approved medicine. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
polypeptide
-
Location:
No. 4, 4th Floor, Building D1, Bili La Park, Lu Shang Road, Dongcheng Street, Economic and Technological Development Zone, Liaocheng City, Shandong Province
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2025
Company Certificates-
Tirzepatide
-
Tirzepatide
-
-
Inquiry History7 Inquiries
Country Product Purchase Quantity Date Posted
United States
Adamax
100 MG Jan 5, 2026
South Korea
adamax
10 G Jun 16, 2026
United Kingdom
Adamax Peptide Nootropic Peptide 100% Safe Delivery 99% Adamax
1 MT Oct 23, 2023
United States
Adamax Raw Powder
50 MG Jun 1, 2026
Italy
Adamax peptide
10 PCS Apr 20, 2026
Italy
Adamax
10 PCS Apr 20, 2026
United States
TR
100 G May 1, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Mazdutide Peptide 50mg 100mg Raw Powder CAS Support Custom Package Factory Bulk Supply
Reagent Grade / 99.9%
$30/UNIT FOB
-
-
-
-
FOXO4 Factory Price 99% Purity Research Grade Peptide Powder, High Quality Low Cost With Door To Door Delivery
Cosmetics Grade / 99%
$300/UNIT FOB
-
-
-
-
Thymalin Self-Produced Source Research Whitening Polypeptide Powder With Industry Best Price, Custom Modified Peptides, Fast Safe Global Delivery
Pharmaceutical Grade / 99.98%
$70/UNIT FOB
-
-
-
-
Epitalon Anti-Aging Peptide 50mg 100mg Raw Powder CAS Support Custom Package Factory Bulk Supply
Reagent Grade / 99.9%
$30/UNIT FOB
-
-
-
-
Retatrutide Peptide 50mg 100mg Raw Powder CAS Support Custom Package Factory Bulk Supply
Reagent Grade / 99.9%
$30/UNIT FOB
-
-
-
-
Thymalin Immune Peptide 50mg 100mg Raw Powder CAS Support Custom Package Factory Bulk Supply
Reagent Grade / 99.9%
$30/UNIT FOB
-
Tirzepatide (LY3298176) is a dual glucose-dependent polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide. Tirzepatide, also known as LY 3298176, is a dual glucose-dependent polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an additio